基于非增强MRI的多层感知机网络分类器预测胰腺导管腺癌患者的肿瘤浸润CD20+ B细胞
回顾性纳入2017年1月至2018年4月病理确诊的156例胰腺导管腺癌患者,利用术前非增强MRI提取1409个影像组学特征构建多层感知机网络分类器预测CD20表达。CD20高表达组生存期22.37个月(95%CI 19.10-25.65)显著长于CD20低表达组14.9个月(95%CI 10.96-18.84);模型训练集与验证集AUC均为0.79。
要点
- CD20高表达组生存期22.37个月,显著长于CD20低表达组14.9个月。
- 基于非增强MRI的影像组学模型预测CD20表达,验证集AUC为0.79。
- 验证集敏感度69.23%、特异度80.95%,准确度0.74。
核心结论
- 基于非增强MRI扫描的多层感知机分类器可预测胰腺导管腺癌患者的CD20表达水平。
研究设计与样本
- 回顾性研究,纳入156例病理确诊的胰腺导管腺癌患者,使用术前非增强MRI,以免疫组化为参考标准,采用最小绝对收缩和选择算子逻辑回归算法筛选1409个影像组学特征,在训练集和验证集中开发多层感知机网络分类器。
诊断标准与关键数值
- 训练集AUC 0.79,敏感度73.21%、特异度75.47%、准确度0.74、阳性预测值0.76、阴性预测值0.73。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Conventional chemotherapy has limited benefit in pancreatic ductal adenocarcinoma (PDAC), necessitating identification of novel therapeutic targets. Radiomics may enable non-invasive prediction of CD20 expression, a hypothesized therapeutic target in PDAC. To develop a machine learning classifier based on noncontrast magnetic resonance imaging for predicting CD20 expression in PDAC.
MATERIALS AND METHODS: Retrospective study was conducted on preoperative noncontrast magnetic resonance imaging of 156 patients with pathologically confirmed PDAC from January 2017 to April 2018. For each patient, 1409 radiomics features were selected using minimum absolute contraction and selective operator logistic regression algorithms. CD20 expression was quantified using immunohistochemistry. A multilayer perceptron network classifier was developed using the training and validation set.
RESULTS: A log-rank test showed that the CD20-high group (22.37 months, 95% CI: 19.10-25.65) had significantly longer survival than the CD20-low group (14.9 months, 95% CI: 10.96-18.84). The predictive model showed good differentiation in training (area under the curve [AUC], 0.79) and validation (AUC, 0.79) sets. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 73.21%, 75.47%, 0.74, 0.76, and 0.73, respectively, for the training set and 69.23%, 80.95%, 0.74, 0.82, and 0.68, respectively, for the validation set.
CONCLUSION: Multilayer perceptron classifier based on noncontrast magnetic resonance imaging scanning can predict the level of CD20 expression in PDAC patients.
引用
- Li, Yu, Zhang, et al. Prediction of Tumor-Infiltrating CD20+ B-Cells in Patients with Pancreatic Ductal Adenocarcinoma Using a Multilayer Perceptron Network Classifier Based on Non-contrast MRI. Acad Radiol. 2021. PMID: 34922828. doi:10.1016/j.acra.2021.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。